Login to Your Account



Other News To Note


Thursday, July 12, 2012
• Gradalis Inc., of Dallas, signed a collaboration agreement with Baylor College of Medicine for the use of Gradalis' bifunctional shRNA platform for research into therapeutic targets in cancer. Under the agreement, Gradalis will contribute shRNA constructs targeted at specific proteins of interest and access to other technologies, including SuperClean DNA, reversible masking, liposomal delivery and liposomal targeting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription